Sarah A. Limbacher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sarah A. Limbacher has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Julia Wrobel
Emory University, Rollins School of Public Health, Department of Biostatistics and Bioinformatics, Atlanta, Georgia, United States of America
5 shared publications- Ashley Brooks-Russell
Department of Community and Behavioral Health, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States
4 shared publications Suneeta Godbole
Stanford Medicine, Quantitative Sciences Unit, Stanford, California, United States of America
4 shared publicationsAshley Brooks-Russell
Colorado School of Public Health, Injury and Violence Prevention Center, Aurora, Colorado, United States of America
2 shared publications- Duncan I. Mackie
MedPharm Holdings LLC, DBA Bud & Mary’s, Denver, Colorado, USA
2 shared publications Jennifer M. Frame
Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, USA
2 shared publications
Latest Publications
- Open Access
- 15 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0321832
Commercial cannabis product testing: Fidelity to labels and regulations
Background: In Colorado, regulations for recreational and medical cannabis sales require tetrahydrocannabinol (THC) concentration is printed on all products. Labeled THC concentrations can vary by +/-15% of what is in the product. Studies show THC concentrations recorded on product labels are not always reflective of the THC concentration in the cannabis product and there is evidence consumers make purchasing decisions based on label claims. Aims: Explore the accuracy of cannabis product labels and differences between THC label accuracy and product type. Design: Data for this analysis come from a larger observational study of cannabis impairment. N = 74 flower, concentrate, and edible product samples from licensed Colorado dispensaries were collected and independently tested for THC concentration. Setting: This study was conducted in Colorado, in the Denver Metro Area. Participants: Participants in the study voluntarily enrolled and provided one-gram samples of the cannabis they consumed during the study to be independently tested. The cannabis tested for this analysis was donated on a voluntary basis, not all participants chose to donate. Measurement: The main outcomes of interest for this analysis are accuracy of cannabis product labels compared to observed THC content, accuracy in the context of legally allowable variation, and difference between accuracy by product. Findings: Overall, label values were higher than observed values in flower and edible products (p < 0.001) but was not significant for concentrates (p = 0.85). Flower products were observed to be significantly lower on labels versus the 15% legally allowable range (p = 0.04). Concentrate and edible products were not significantly different (p = 0.9 and p = 0.5, respectively). Conclusions: There is tension between legally allowable THC concentration claims on cannabis product labels and how consumers purchase cannabis. As cannabis policy evolves, standards and regulations that ensure accurate THC concentrations are reported on product labels are urgently needed.
- 15 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0321832
Open AccessCommercial cannabis product testing: Fidelity to labels and regulations
Background: In Colorado, regulations for recreational and medical cannabis sales require tetrahydrocannabinol (THC) concentration is printed on all products. Labeled THC concentrations can vary by +/-15% of what is in the product. Studies show THC concentrations recorded on product labels are not always reflective of the THC concentration in the cannabis product and there is evidence consumers make purchasing decisions based on label claims. Aims: Explore the accuracy of cannabis product labels and differences between THC label accuracy and product type. Design: Data for this analysis come from a larger observational study of cannabis impairment. N = 74 flower, concentrate, and edible product samples from licensed Colorado dispensaries were collected and independently tested for THC concentration. Setting: This study was conducted in Colorado, in the Denver Metro Area. Participants: Participants in the study voluntarily enrolled and provided one-gram samples of the cannabis they consumed during the study to be independently tested. The cannabis tested for this analysis was donated on a voluntary basis, not all participants chose to donate. Measurement: The main outcomes of interest for this analysis are accuracy of cannabis product labels compared to observed THC content, accuracy in the context of legally allowable variation, and difference between accuracy by product. Findings: Overall, label values were higher than observed values in flower and edible products (p < 0.001) but was not significant for concentrates (p = 0.85). Flower products were observed to be significantly lower on labels versus the 15% legally allowable range (p = 0.04). Concentrate and edible products were not significantly different (p = 0.9 and p = 0.5, respectively). Conclusions: There is tension between legally allowable THC concentration claims on cannabis product labels and how consumers purchase cannabis. As cannabis policy evolves, standards and regulations that ensure accurate THC concentrations are reported on product labels are urgently needed.
- 18 September 2025
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 63 (11) , 869-877
Pupillary dynamics as a marker of acute cannabis inhalation
Acute cannabis use has been found to affect pupil size and pupillary dynamics. Law enforcement may consider ocular changes in their examinations to determine drug impairment and the source, including from cannabis. A limited number of studies have used pupillometer technology to provide an objective measure of pupillary changes associated with cannabis use. The purpose of the study was to examine the sensitivity and specificity of pupil size and dynamics, measured with a pupillometer, associated with recent cannabis inhalation. Participants (n = 126) completed a pupillometer assessment, using the NeurOptics PLR-3000 at three times. Of the 126 participants, 95 completed assessments at baseline, and at 40 min and 100 min following 15 min of ad libitum inhalation of self-provided cannabis flower or concentrate products. Thirty-one participants completed the same assessments without using cannabis. Sensitivity, specificity and accuracy were calculated for pupil size and dynamics measures associated with recent cannabis use versus no use, for both post-use time points. Least absolute shrinkage and selection operator models were used to identify the combination of ocular metrics that were most predictive and parsimonious. Following cannabis use, the pupillary measure with the highest area under the curve was percent change in pupil size, which decreased after cannabis use, with an area under the curve of 0.73 at 40 min and 0.75 at 100 min following cannabis use. Considering variables together in a least absolute shrinkage and selection operator model did not meaningfully improve prediction over individual measures. Consistent with some prior studies, we did not find that cannabis use was associated with substantial and consistent change in the maximum pupil size (measured in darkness) relative to controls. However, diminished pupil dynamics, such as constriction in response to light and recovery dilation, were more predictive of recent cannabis use, consistent with limited prior studies. Pupillary dynamics, when measured with an objective test, may contribute to providing an indication of recent cannabis inhalation.
- 18 September 2025
- Published by Taylor & Francis in Clinical Toxicology
- Vol. 63 (11) , 869-877
Pupillary dynamics as a marker of acute cannabis inhalation
Acute cannabis use has been found to affect pupil size and pupillary dynamics. Law enforcement may consider ocular changes in their examinations to determine drug impairment and the source, including from cannabis. A limited number of studies have used pupillometer technology to provide an objective measure of pupillary changes associated with cannabis use. The purpose of the study was to examine the sensitivity and specificity of pupil size and dynamics, measured with a pupillometer, associated with recent cannabis inhalation. Participants (n = 126) completed a pupillometer assessment, using the NeurOptics PLR-3000 at three times. Of the 126 participants, 95 completed assessments at baseline, and at 40 min and 100 min following 15 min of ad libitum inhalation of self-provided cannabis flower or concentrate products. Thirty-one participants completed the same assessments without using cannabis. Sensitivity, specificity and accuracy were calculated for pupil size and dynamics measures associated with recent cannabis use versus no use, for both post-use time points. Least absolute shrinkage and selection operator models were used to identify the combination of ocular metrics that were most predictive and parsimonious. Following cannabis use, the pupillary measure with the highest area under the curve was percent change in pupil size, which decreased after cannabis use, with an area under the curve of 0.73 at 40 min and 0.75 at 100 min following cannabis use. Considering variables together in a least absolute shrinkage and selection operator model did not meaningfully improve prediction over individual measures. Consistent with some prior studies, we did not find that cannabis use was associated with substantial and consistent change in the maximum pupil size (measured in darkness) relative to controls. However, diminished pupil dynamics, such as constriction in response to light and recovery dilation, were more predictive of recent cannabis use, consistent with limited prior studies. Pupillary dynamics, when measured with an objective test, may contribute to providing an indication of recent cannabis inhalation.
- 12 June 2025
- Published by Taylor & Francis in Traffic Injury Prevention
- Vol. 26 (sup1) , 1-10
Impact of naturalistic cannabis use on lateral control and speed: A driving simulator study
Cannabis has been shown to impair driving performance, but much of extant research has been conducted with relatively low concentration products, not reflective of the marketplace in states with legal adult recreational cannabis use. The study examined driving performance after cannabis use, inclusive of high concentration tetrahydrocannabinol (THC) products. Participants (n = 118) completed three 20-minute simulated drives, with rural and urban segments. The study was within-subjects; participants completed a pre-use (baseline) drive, and two post-use drives at approximately 30 min and an hour and a half after cannabis use. Of participants, n = 89 inhaled cannabis products (flower or concentrates) ad libitum for up to 15 min and n = 29 participants completed the protocol without using cannabis. Outcomes included lane departures, standard deviation of lateral placement [SDLP], average speed, and standard deviation of speed. Primary predictors were time-point, and group based on cannabis use frequency and product used in the study (control group; occasional-flower; daily-flower; daily-concentrate). There were significant changes in lane departures, SDLP and speed measures from baseline to post use, depending on the participant group and time point. When compared to the control group, the occasional-flower group had a greater increase in rate of lane departures (0.16 departures/minute at baseline and 0.47 at Post 1, p < 0.01). In contrast, the daily-concentrate group had an improvement in SDLP (27.2 to 26.1 cm at Post 1) compared to the control group (23.9 to 25.7 cm; p = 0.04). The daily-flower and occasional-flower groups had little to no change in average speed from pre- to post-cannabis use (e.g., 53.9 mph at baseline and Post 1, daily-flower group) whereas the control group increased speed (e.g., 53.9 to 54.6 mph, baseline to Post 1). There were additional significant differences between the groups. Within and between group differences in change were relatively small. The occasional-flower group exhibited an increase in lane departures, not seen in other groups, consistent with tolerance in the daily-use groups. There was a notable absence of declines in driving performance for the daily-concentrate group. Changes in driving performance were relatively small across all groups.
- 12 June 2025
- Published by Taylor & Francis in Traffic Injury Prevention
- Vol. 26 (sup1) , 1-10
Impact of naturalistic cannabis use on lateral control and speed: A driving simulator study
Cannabis has been shown to impair driving performance, but much of extant research has been conducted with relatively low concentration products, not reflective of the marketplace in states with legal adult recreational cannabis use. The study examined driving performance after cannabis use, inclusive of high concentration tetrahydrocannabinol (THC) products. Participants (n = 118) completed three 20-minute simulated drives, with rural and urban segments. The study was within-subjects; participants completed a pre-use (baseline) drive, and two post-use drives at approximately 30 min and an hour and a half after cannabis use. Of participants, n = 89 inhaled cannabis products (flower or concentrates) ad libitum for up to 15 min and n = 29 participants completed the protocol without using cannabis. Outcomes included lane departures, standard deviation of lateral placement [SDLP], average speed, and standard deviation of speed. Primary predictors were time-point, and group based on cannabis use frequency and product used in the study (control group; occasional-flower; daily-flower; daily-concentrate). There were significant changes in lane departures, SDLP and speed measures from baseline to post use, depending on the participant group and time point. When compared to the control group, the occasional-flower group had a greater increase in rate of lane departures (0.16 departures/minute at baseline and 0.47 at Post 1, p < 0.01). In contrast, the daily-concentrate group had an improvement in SDLP (27.2 to 26.1 cm at Post 1) compared to the control group (23.9 to 25.7 cm; p = 0.04). The daily-flower and occasional-flower groups had little to no change in average speed from pre- to post-cannabis use (e.g., 53.9 mph at baseline and Post 1, daily-flower group) whereas the control group increased speed (e.g., 53.9 to 54.6 mph, baseline to Post 1). There were additional significant differences between the groups. Within and between group differences in change were relatively small. The occasional-flower group exhibited an increase in lane departures, not seen in other groups, consistent with tolerance in the daily-use groups. There was a notable absence of declines in driving performance for the daily-concentrate group. Changes in driving performance were relatively small across all groups.
- Open Access
Commercial Cannabis Product Testing: Fidelity to Labels and Regulations
Background: In Colorado, regulations for recreational and medical cannabis sales require Tetrahydrocannabinol (THC) concentration is printed on all products. Labeled THC concentrations can vary by +/-15% of what is in the product. Studies show THC concentrations recorded on product labels are not always reflective of the THC concentration in the cannabis product and there is evidence consumers make purchasing decisions based on label claims. Aims: Explore the accuracy of cannabis product labels and differences between THC label accuracy and product type. Design: Data for this analysis come from a larger observational study of cannabis impairment. N=74 flower, concentrate, and edible product samples from licensed Colorado dispensaries were collected and independently tested for THC concentration. Setting: This study was conducted in Colorado, in the Denver Metro Area. Participants: Participants in the study voluntarily enrolled and provided one-gram samples of the cannabis they consumed during the study to be independently tested. The cannabis tested for this analysis was donated on a voluntary basis, not all participants chose to donate. Measurement: The main outcomes of interest for this analysis are accuracy of cannabis product labels compared to observed THC content, accuracy in the context of legally allowable variation, and difference between accuracy by product. Findings: Overall, label values were higher than observed values in flower and edible products (p < 0.001) but was not significant for concentrates (p = 0.85). Flower products were observed to be significantly lower on labels versus the 15% legally allowable range (p = 0.04). Concentrate and edible products were not significantly different (p = 0.9 and p = 0.5, respectively). Conclusions: There is tension between legally allowable THC concentration claims on cannabis product labels and how consumers purchase cannabis. As cannabis policy evolves, standards and regulations that ensure accurate THC concentrations are reported on product labels are urgently needed.
Open AccessCommercial Cannabis Product Testing: Fidelity to Labels and Regulations
Background: In Colorado, regulations for recreational and medical cannabis sales require Tetrahydrocannabinol (THC) concentration is printed on all products. Labeled THC concentrations can vary by +/-15% of what is in the product. Studies show THC concentrations recorded on product labels are not always reflective of the THC concentration in the cannabis product and there is evidence consumers make purchasing decisions based on label claims. Aims: Explore the accuracy of cannabis product labels and differences between THC label accuracy and product type. Design: Data for this analysis come from a larger observational study of cannabis impairment. N=74 flower, concentrate, and edible product samples from licensed Colorado dispensaries were collected and independently tested for THC concentration. Setting: This study was conducted in Colorado, in the Denver Metro Area. Participants: Participants in the study voluntarily enrolled and provided one-gram samples of the cannabis they consumed during the study to be independently tested. The cannabis tested for this analysis was donated on a voluntary basis, not all participants chose to donate. Measurement: The main outcomes of interest for this analysis are accuracy of cannabis product labels compared to observed THC content, accuracy in the context of legally allowable variation, and difference between accuracy by product. Findings: Overall, label values were higher than observed values in flower and edible products (p < 0.001) but was not significant for concentrates (p = 0.85). Flower products were observed to be significantly lower on labels versus the 15% legally allowable range (p = 0.04). Concentrate and edible products were not significantly different (p = 0.9 and p = 0.5, respectively). Conclusions: There is tension between legally allowable THC concentration claims on cannabis product labels and how consumers purchase cannabis. As cannabis policy evolves, standards and regulations that ensure accurate THC concentrations are reported on product labels are urgently needed.
- Open Access
- 23 May 2024
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 46 (5) , 672-680
Dose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled Δ9-Tetrahydrocannabinol Cannabis Market Products in Occasional and Daily Users
Background: Unusually high variability in blood Δ9-tetrahydrocannabinol (THC) concentrations have been observed in subjects inhaling similar cannabis products over similar time periods when consumption is ad libitum. This makes simple gravimetric dose estimation a poor predictor of THC exposure. Population pharmacokinetic analyses of blood THC concentration versus time data are routinely used to estimate pharmacokinetic parameters. The aim of this study was to estimate the inhaled dose of THC in occasional and daily users of high potency market cannabis. Methods: Blood THC concentrations were measured for 135 minutes from 29 participants who either smoked high concentration flower or inhaled concentrates ad libitum during a 15-minute session. Frequent blood samples were obtained over the following 135 minutes. Results: The estimated central and rapidly equilibrating volumes of distribution of a 3-compartment model were 19.9 ± 1.2 and 51.6 ± 4.7 L whereas the intercompartmental clearances were 1.65 ± 0.14 and 1.75 ± 0.10 L/min, respectively. Covariate-adjusted analysis revealed that the estimated inhaled THC dose was considerably less among occasional users compared with daily users. Conclusions: Three-compartment pharmacokinetics of THC did not differ among the 3 user groups, and the early phase (first 135 minutes postinception of inhalation) kinetics were similar to those previously described after smoking low potency cannabis products. Therefore, inhaled THC dose can be estimated from pharmacokinetic data and covariate-driven adjustments can be used to estimate THC doses, based on the participant cannabis usage pattern (occasional versus daily), improving the accuracy of THC exposure estimates compared with those derived from weighed THC content alone.
- 23 May 2024
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 46 (5) , 672-680
Open AccessDose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled Δ9-Tetrahydrocannabinol Cannabis Market Products in Occasional and Daily Users
Background: Unusually high variability in blood Δ9-tetrahydrocannabinol (THC) concentrations have been observed in subjects inhaling similar cannabis products over similar time periods when consumption is ad libitum. This makes simple gravimetric dose estimation a poor predictor of THC exposure. Population pharmacokinetic analyses of blood THC concentration versus time data are routinely used to estimate pharmacokinetic parameters. The aim of this study was to estimate the inhaled dose of THC in occasional and daily users of high potency market cannabis. Methods: Blood THC concentrations were measured for 135 minutes from 29 participants who either smoked high concentration flower or inhaled concentrates ad libitum during a 15-minute session. Frequent blood samples were obtained over the following 135 minutes. Results: The estimated central and rapidly equilibrating volumes of distribution of a 3-compartment model were 19.9 ± 1.2 and 51.6 ± 4.7 L whereas the intercompartmental clearances were 1.65 ± 0.14 and 1.75 ± 0.10 L/min, respectively. Covariate-adjusted analysis revealed that the estimated inhaled THC dose was considerably less among occasional users compared with daily users. Conclusions: Three-compartment pharmacokinetics of THC did not differ among the 3 user groups, and the early phase (first 135 minutes postinception of inhalation) kinetics were similar to those previously described after smoking low potency cannabis products. Therefore, inhaled THC dose can be estimated from pharmacokinetic data and covariate-driven adjustments can be used to estimate THC doses, based on the participant cannabis usage pattern (occasional versus daily), improving the accuracy of THC exposure estimates compared with those derived from weighed THC content alone.
- 1 February 2024
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 10 (1) , 53-59
Dose of Product or Product Concentration: A Comparison of Change in Heart Rate by THC Concentration for Participants Using Cannabis Daily and Occasionally
Introduction: Studies show that acute cannabis use significantly increases heart rate (HR) and mildly raises blood pressure in the minutes following smoked or inhaled use of cannabis. However, less is known about how the THC concentration of the product or an individual’s frequency of use (i.e., tolerance) may affect the magnitude of the change in HR. It is also relatively unexamined how the physical effects of increased HR after acute cannabis use relate to self-reported drug effects or blood THC levels. Aims: To describe the relationship between THC concentration of product used, self-reported subjective intoxication, THC blood levels, and frequency of cannabis use with the change in HR after acute cannabis use. Materials and Methods: Participants ( n = 140) were given 15 min to smoke self-supplied cannabis ad libitum , HR was measured at baseline and an average of 2 min post-cannabis smoking. The ARCI-Marijuana scale and Visual Analog Scales (VAS) were administered, and blood samples were taken at both time points. Participants were asked about their frequency of use. Information about the product used was recorded from the package. Linear regression was used to analyze the relationship between changes in HR (post-pre cannabis use) and post-cannabis use HR, blood THC concentration, THC product concentration, frequency of use, and self-reported drug effect. Results: There was a significantly higher HR among those who smoked cannabis compared to the controls ( p < 0.001), which did not significantly differ by frequency of use ( p = 0.18). Higher concentration THC (extract) products did not produce a significantly different HR than lower concentration (flower) products ( p = 0.096). VAS score was associated with an increase in HR ( p < 0.05). Overall, blood THC levels were not significantly related to the change in HR ( p = 0.69); however, when probed, there was a slight positive association among the occasional use group only. Discussion: Cardiovascular effects of cannabis consumption may not be as subject to tolerance with daily cannabis use and do not directly increase with THC concentration of the product. This is a departure from other effects (i.e., cognitive, subjective drug effects) where tolerance is well established. These findings also suggest that, at least among those with daily use, higher concentration THC products (>60%) do not necessarily produce cardiovascular physiological effects that are significantly more robust than lower concentration (<20%) products.
- 1 February 2024
- Published by SAGE Publications in Cannabis & Cannabinoid Research
- Vol. 10 (1) , 53-59
Dose of Product or Product Concentration: A Comparison of Change in Heart Rate by THC Concentration for Participants Using Cannabis Daily and Occasionally
Introduction: Studies show that acute cannabis use significantly increases heart rate (HR) and mildly raises blood pressure in the minutes following smoked or inhaled use of cannabis. However, less is known about how the THC concentration of the product or an individual’s frequency of use (i.e., tolerance) may affect the magnitude of the change in HR. It is also relatively unexamined how the physical effects of increased HR after acute cannabis use relate to self-reported drug effects or blood THC levels. Aims: To describe the relationship between THC concentration of product used, self-reported subjective intoxication, THC blood levels, and frequency of cannabis use with the change in HR after acute cannabis use. Materials and Methods: Participants ( n = 140) were given 15 min to smoke self-supplied cannabis ad libitum , HR was measured at baseline and an average of 2 min post-cannabis smoking. The ARCI-Marijuana scale and Visual Analog Scales (VAS) were administered, and blood samples were taken at both time points. Participants were asked about their frequency of use. Information about the product used was recorded from the package. Linear regression was used to analyze the relationship between changes in HR (post-pre cannabis use) and post-cannabis use HR, blood THC concentration, THC product concentration, frequency of use, and self-reported drug effect. Results: There was a significantly higher HR among those who smoked cannabis compared to the controls ( p < 0.001), which did not significantly differ by frequency of use ( p = 0.18). Higher concentration THC (extract) products did not produce a significantly different HR than lower concentration (flower) products ( p = 0.096). VAS score was associated with an increase in HR ( p < 0.05). Overall, blood THC levels were not significantly related to the change in HR ( p = 0.69); however, when probed, there was a slight positive association among the occasional use group only. Discussion: Cardiovascular effects of cannabis consumption may not be as subject to tolerance with daily cannabis use and do not directly increase with THC concentration of the product. This is a departure from other effects (i.e., cognitive, subjective drug effects) where tolerance is well established. These findings also suggest that, at least among those with daily use, higher concentration THC products (>60%) do not necessarily produce cardiovascular physiological effects that are significantly more robust than lower concentration (<20%) products.
- 25 November 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (12) , 9901-9907
Early-stage breast cancer menopausal symptom experience and management: exploring medical oncology clinic visit conversations through qualitative analysis
Purpose Women being treated with chemotherapy for breast cancer experience menopausal symptoms that vary in presentation and impact on quality of life. The clinical visit before each chemotherapy cycle provides an important opportunity to allow patients to dialogue with their medical oncology healthcare providers about these symptoms and identify strategies for self-management. The objective of this study was to characterize patient and provider interactions regarding the menopausal symptom experience and management in the context of breast cancer treatment. Methods Thematic analysis was employed to analyze 61 transcripts from clinical encounters of women receiving chemotherapy treatment for breast cancer. Transcripts were chosen based on their inclusion of menopausal symptom discussion. Results Themes were separated into three distinct categories: patient, clinician, and dyadic themes. The overarching theme was goal discordance in the clinical visit, which was reflected in the following themes: unexpected and unprepared; distressed, disrupted and disturbed; clinical insensitivity; missed opportunity for management and empathy; and use of humor and colloquial language. Overall, women were unprepared for the menopausal symptom experience, and clinicians did not often provide management, interventions, or empathetic responses. Conclusion There is a need to develop more astute assessment and communication regarding menopausal symptoms during the clinical visit. Possible interventions include a more holistic assessment, algorithms to facilitate the clinician’s attention and response to menopausal symptoms, and treatment of symptoms.
- 25 November 2022
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 30 (12) , 9901-9907
Early-stage breast cancer menopausal symptom experience and management: exploring medical oncology clinic visit conversations through qualitative analysis
Purpose Women being treated with chemotherapy for breast cancer experience menopausal symptoms that vary in presentation and impact on quality of life. The clinical visit before each chemotherapy cycle provides an important opportunity to allow patients to dialogue with their medical oncology healthcare providers about these symptoms and identify strategies for self-management. The objective of this study was to characterize patient and provider interactions regarding the menopausal symptom experience and management in the context of breast cancer treatment. Methods Thematic analysis was employed to analyze 61 transcripts from clinical encounters of women receiving chemotherapy treatment for breast cancer. Transcripts were chosen based on their inclusion of menopausal symptom discussion. Results Themes were separated into three distinct categories: patient, clinician, and dyadic themes. The overarching theme was goal discordance in the clinical visit, which was reflected in the following themes: unexpected and unprepared; distressed, disrupted and disturbed; clinical insensitivity; missed opportunity for management and empathy; and use of humor and colloquial language. Overall, women were unprepared for the menopausal symptom experience, and clinicians did not often provide management, interventions, or empathetic responses. Conclusion There is a need to develop more astute assessment and communication regarding menopausal symptoms during the clinical visit. Possible interventions include a more holistic assessment, algorithms to facilitate the clinician’s attention and response to menopausal symptoms, and treatment of symptoms.
- Open Access
- 23 September 2022
- Published by Springer Nature in Research Square
Early-Stage Breast Cancer Menopausal Symptom Experience and Management: Exploring Medical Oncology Clinic Visit Conversations Through Qualitative Analysis
Purpose Women being treated with chemotherapy for breast cancer experience menopausal symptoms that vary in presentation and impact on quality of life. The clinical visit before each chemotherapy cycle provides an important opportunity to allow patients to dialogue with their medical oncology healthcare providers about these symptoms and identify strategies for self-management. The objective of this study was to characterize patient and provider interactions regarding the menopausal symptom experience and management in the context of breast cancer treatment. Methods Thematic analysis was employed to analyze 61 transcripts from clinical encounters of women receiving chemotherapy treatment for breast cancer. Transcripts were chosen based on their inclusion of menopausal symptom discussion. Results Themes were separated into three distinct categories: patient, clinician, and dyadic themes. The overarching theme was goal discordance in the clinical visit, which was reflected in the following themes: unexpected & unprepared, distressed, disrupted & disturbed, clinical insensitivity, missed opportunity for management and empathy, and use of humor and colloquial language. Overall, women were unprepared for the menopausal symptom experience and clinicians did not often provide management, interventions, or empathetic responses. Conclusion There is a need to develop more astute assessment and communication regarding menopausal symptoms during the clinical visit. Possible interventions include a more holistic assessment, algorithms to facilitate the clinician’s attention and response to menopausal symptoms, and treatment of symptoms.
- 23 September 2022
- Published by Springer Nature in Research Square
Open AccessEarly-Stage Breast Cancer Menopausal Symptom Experience and Management: Exploring Medical Oncology Clinic Visit Conversations Through Qualitative Analysis
Purpose Women being treated with chemotherapy for breast cancer experience menopausal symptoms that vary in presentation and impact on quality of life. The clinical visit before each chemotherapy cycle provides an important opportunity to allow patients to dialogue with their medical oncology healthcare providers about these symptoms and identify strategies for self-management. The objective of this study was to characterize patient and provider interactions regarding the menopausal symptom experience and management in the context of breast cancer treatment. Methods Thematic analysis was employed to analyze 61 transcripts from clinical encounters of women receiving chemotherapy treatment for breast cancer. Transcripts were chosen based on their inclusion of menopausal symptom discussion. Results Themes were separated into three distinct categories: patient, clinician, and dyadic themes. The overarching theme was goal discordance in the clinical visit, which was reflected in the following themes: unexpected & unprepared, distressed, disrupted & disturbed, clinical insensitivity, missed opportunity for management and empathy, and use of humor and colloquial language. Overall, women were unprepared for the menopausal symptom experience and clinicians did not often provide management, interventions, or empathetic responses. Conclusion There is a need to develop more astute assessment and communication regarding menopausal symptoms during the clinical visit. Possible interventions include a more holistic assessment, algorithms to facilitate the clinician’s attention and response to menopausal symptoms, and treatment of symptoms.